title: [The role of β-blockers in patients with metabolic syndrome and hypertension].
abstract: The choice of treatment of patients with hypertension should not be based solely on the blood pressure value, because the risk of cardiovascular diseases are influenced by the presence and magnitude of other risk factors, too. The presence of a metabolic disease (diabetes mellitus, metabolic syndrome) itself categorizes the patient as a high risk individual. In such cases the use of combined treatment is usually considered. For example, in case of hypertension aggravated by left ventricular dysfunction, ischaemic heart disease or cardiac insufficiency, β-blocker treatment is usually included in the combination of the first setting.
authors: Petz Aladár Megyei Oktató Kórház Kardiológiai Osztály Győr Vasvári Pál út 2-4. 9024.
authors: Csaba András
authors: CA
authors: Dézsi
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D006331:Heart Diseases / Q000150:complications* / Q000503:physiopathology; D006333:Heart Failure / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000150:complications* / Q000503:physiopathology; D017202:Myocardial Ischemia / Q000150:complications; D012307:Risk Factors; D018487:Ventricular Dysfunction, Left / Q000150:complications
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents
keywords: anyagcsere-semleges beta-blokkoló; beta-blocker with neutral metabolic effect; diabetes mellitus; hypertension; hypertonia; metabolic syndrome; metabolikus szindróma